RenovoRx, Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025. The amendment is limited to revising Part I, Item 1A (Risk Factors) and Part II, Item 9A (Controls and Procedures). Management confirmed that previously identified material weaknesses in internal control over financial reporting were remediated as of December 31, 2025. The company reported net losses of approximately $11.2 million for the fiscal year ended December 31, 2025, compared to $8.8 million in 2024. Revenue from RenovoCath commercial sales reached approximately $1.1 million in 2025, up from $43,000 in 2024. As of March 23, 2026, the company held approximately $13.0 million in cash and cash equivalents.